



- Immunogenicity studies (detection of ADAs and nAbs)
- Detection of cytokines, chemokines and other biomarkers
- Affinity determinations and potency estimations

Multiplexing with Meso Scale Discovery (MSD)

Development of Biologics: Our Experience – Your Track to Success

IBR Inc. is a Swiss GxPcompliant contract research organization founded in 1998. With a focus on bioanalytical services for therapeutic antibodies, biologics, antibody-drug conjugates and vaccines, IBR Inc. is covering the bioanalytical needs from pre-clinical and clinical development to manufacturing. Beside a broad panel of classical bioanalytical methods, IBR Inc. offers advanced technologies including Alpha technology, TR-FRET, MSD ECL, Gyrolab™, flow cytometry, multiplex cytometric bead array and quantitative PCR. The IBR Inc. team has vast experience with primary cells, transformed cell lines and transfected reportergene cell systems as well as longstanding expertise on 2D and 3D cell based assays. IBR Inc. supports your studies from assay development to assay validation and sample measurement.



COMPLIANT TEST FACILITY


Bioanalytical Laboratories Lauchefeld 31 CH-9548 Matzingen Switzerland Phone: +41 52 366 3520 FAX: +41 52 366 3521 www.ibr-inc.com IBR Inc. offers the MSD ECL immunoassay platform with its SECTOR S 600 which is a powerful tool whenever an assay demands multiplexing with retained high sensitivity, even in complex matrices, such as serum or plasma. Regardless whether a direct, indirect, sandwich or bridging format is required, the MSD ECL technology allows rapid development of robust immunoassays to achieve straightforward validation and subsequent sample measurement.

Principle

MSD combines the MULTI-ARRAY technology with ECL to deliver high density information. The multi-spot plates are available in 96- and 384- well formats with up to 10 array spots per well. The high binding carbon electrodes of the assay plate enables easy attachment of a broad variety of reagents including antibodies and non-antibody molecules (carbohydrates, viruslike particles, peptides and membrane lysates). The surface is even eligible for spreading of living cells. The MSD SULFO-TAG™ label can be easily conjugated to any detection antibody. When the detection antibody comes in close proximity to the plate electrodes and electricity is applied, a series of reduction and oxidation reactions are set in motion. This results in light emission at ~620 nm and allows quantitative measurement of analytes in the sample.

Applications

The MSD System is a versatile platform that finds its application throughout all phases of biopharmaceutical development. MSD ECL is an excellent system to detect ADAs, nAbs, cytokines, chemokines and other biomarkers as well as therapeutic antibody-antigen interactions for affinity determinations and potency estimations with high sensitivity and broad dynamic range. Compared to conventional ELISA, the MSD platform has the advantage of being a multiplexing technique ideally suited to supporting time-saving laboratory procedures.



Protein / Antigen Carbohydrates Virus-like Particles

Membranes

Cells

IBR INC., INSTITUTE FOR BIOPHARMACEUTICAL RESEARCH